LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)

Authors :: Giovanni Scambia
Kathleen N. Moore
Salvatore Antonio Pignata
Nicoletta Colombo
Luciana Molinero
K. Robison
Carol Aghajanian
Johanna Mäenpää
Anthony B. Miller
Charles K. Anderson
Michael A. Bookman
L.J. Willmott
J. Thomes-Pepin
Victor Khor
M.A. Gold
Tashanna Myers
Yvonne G. Lin
F. Wu
Jalid Sehouli
Cagatay Taskiran
Source :: Annals of Oncology. 31:S1161-S1162
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
medicine.medical_specialty
Bevacizumab
business.industry
Hematology
Newly diagnosed
medicine.disease
Placebo
Double blind
Atezolizumab
Internal medicine
medicine
Stage (cooking)
Ovarian cancer
business
medicine.drug

Tools